Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

President Trump's potential new tariffs on medicines raise concerns among investors, triggering declines in pharmaceutical ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

Merida Bio launched with $121 million in Series A financing to develop new class of precision therapeutics designed to eliminate antibody drivers.

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Over the last 7 days, the United States market has experienced a drop of 9.4%, contributing to a 3.4% decline over the past year, although earnings are forecast to grow by 14% annually. In this ...

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...

RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on April 3 and set a price target of $330.00.

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...